Business Wire

CO-SPATIAL-CORP

30.4.2024 09:01:33 CEST | Business Wire | Press release

Share
Spatial Announces Release 2024 1.0.1

Spatial Corp, the leading software development toolkit provider for design, manufacturing, and engineering solutions and Dassault Systèmes subsidiary, announces the production release of 2024 1.0.1.

Data Prep Is Officially Released

Open New Horizons in Data Import

After launching the alpha version, Data Prep, Spatial’s newest add-on product for 3D InterOp, is officially released to all customers. Supported strategies include filtering small bodies from a model, removing small holes and fillets, and generating an assembly structure from a part with duplicate bodies.

Over the past three months, customer interest confirms the market need for tools to simplify and optimize data during import. Spatial plans to invest further in Data Prep strategies. Functionality releasing soon includes:

  • Capabilities to reduce data to manage while preserving relevant features - to shorten model preparation times for multi-physics and process simulation workflows.
  • Ability to convert polyline data to continuous curves during file restore - to decrease memory consumption and allow for successful import.
  • Option to avoid model shrinkage due to Data Prep strategies like feature removal - to ensure accuracy of collision detection analyses.

Users interested in defining future strategies for Data Prep should contact their account manager.

3D InterOp Extends Support for BIM and Manufacturing

New Support for Navisworks and Writing DXF/DWG Drawing Sheets

The latest release allows BIM customers to read Navisworks files and write drawing sheets in a DXF/DWG format. Additionally, 3D InterOp offers expanded support for the Linux platform in Parasolid-based 3D InterOp.

Point and Table Patterns from Creo Files

Manufacturing relies on hole pattern metadata for automated machining processes such as drilling, milling, cutting, or punching. The latest release of 3D InterOp supports Point and Table type hole patterns in Creo Reader.

Enabling Support of More Formats through External Partners

Extensible 3D InterOp enables partners to create readers and writers for unsupported file formats. These external implementations integrate with existing formats to seamlessly exchange BREP and Visualization data. Customers wishing to develop custom readers and writers can reach out to their account manager for assistance.

Package Size Optimization

For customers not needing support for all bundled formats, ACIS-based 3D InterOp offers guidance on configuring a minimal library set for popular CAD and exchange formats. This minimizes the libraries shipped with their application, saving end-user disk space. For example, supporting only IGES + STEP formats reduces installed library size by 70%.

3D ACIS Modeler Improves Polyhedral Modeling

Polyhedral Sheet Thickening

Additive manufacturing or EDA workflows often start with input that is a 2D representation of a thin part to be processed. When printing or simulating the part, generating a realistic 3D model representing the object with its actual thickness is helpful. This release delivers an API to generate a thickened body from polyhedral sheets.

New Polyhedral Boolean Operations

ACIS now provides functionality to compute the intersection graph between two polyhedral bodies. It also allows combining disjointed polyhedral bodies into a single body, increasing the efficiency of downstream operations.

CGM Provides More Manufacturing Automation and Simulation Tools

Enhancements to Feature Recognition and Removal

Users can now specify an industry context to customize the behavior of feature recognition. Setting the industry context tailors feature recognition to provide intuitive results for applications as diverse as Body-in-White, Micro-Mechanics, and Civil Engineering. This release also offers functionality to remove chamfers.

Improved Polyhedral Modeling for Additive Manufacturing

This release provides various robustness and performance enhancements targeting polyhedral healing and offset. For both types of operations, options are now available to tune the performance for specific configurations.

New Medial Axis Extraction Operator

Simulation engineers need tools to simplify the geometry of parts to reduce analysis computation time. This release features the beta version of the Neutral Fiber Operator, which reduces radially symmetric 3D bodies to a one-dimensional line.

CSM/CVM: Improvements to Cartesian Core Workflows

CVM generates Cartesian elements for interior meshing, resulting in accurate triangular surface meshes and predominantly hexahedral volume meshes. Users can now control the size of these elements, which were previously determined automatically based on surface mesh element size.

About Spatial Corp.

Spatial Corp, a Dassault Systèmes subsidiary, is the leading provider of 3D software development toolkits for technical applications across a broad range of industries. Spatial 3D modeling, 3D visualization, and CAD translation software development toolkits help application developers deliver market-leading products, maintain focus on core competencies, and reduce time-to-market. For over 35 years, Spatial’s 3D software development toolkits have been adopted by many of the world’s most recognized software developers, manufacturers, research institutes, and universities. Headquartered in Broomfield, Colorado, Spatial has offices in the USA, Germany, Japan, China, and the United Kingdom. For more information, visit www.spatial.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430297301/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye